|
Title
|
|
|
|
Differences in thromboembolic complications between paroxysmal and persistent atrial fibrillation patients following electrical cardioversion (from the ENSURE-AF Study)
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| It is unclear if patients with paroxysmal atrial fibrillation (AF) and persistent AF have different outcomes following electrical cardioversion (ECV). ENSURE-AF-a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation trial-compared once-daily edoxaban 60 mg with enoxaparin-warfarin in 2,199 subjects undergoing ECV of nonvalvular AF (NCT02072434). Patients received >= 3 weeks of proper anticoagulation or transesophageal echocardiogram before ECV paroxysmal AF was defined as AF with spontaneous conversion of duration of < 7 days; persistent AF was defined as AF lasting >= 7 days without spontaneous conversion. Clinical characteristics and outcomes were compared between subjects based on type of AF present at baseline. In total, 415 subjects had paroxysmal AF; 1,777 had persistent AF. Patients with paroxysmal AF were older (65.8 +/- 10.3 vs 63.9 +/- 10.5, p = 0.001) with more hypertension (82.7% vs 77.2%, p = 0.01) versus persistent AF patients. Congestive heart failure was more common in persistent AF (46.7%) versus paroxysmal AF (31.3%, p<0.0001). CHA(2)DS(2)-VASc (score >2: 52.0% vs 49.5%, p = 0.4375) and prior myocardial infarction (6.5% vs 6.8%, p = 0.91) did not significantly differ between groups. After ECV, primary endpoint events were numerically higher in paroxysmal AF versus persistent AF (1.5% vs 0.6%, p = 0.0571), approaching statistical significance. Of note, myocardial infarction was observed in paroxysmal AF (n = 4 vs 0), whereas persistent AF was accompanied by stroke (n = 0 vs 5; p <0.05). In conclusion, patients with paroxysmal AF had more frequent major cardiovascular events than patients with persistent AF. Composite event rates were driven mainly by myocardial infarction in patients with paroxysmal AF and by stroke in those with persistent AF. Overall, the absolute number of events was low after ECV under anticoagulation. (C) 2020 Elsevier Inc. All rights reserved. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The American journal of cardiology. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2020
| |
|
ISSN
|
|
|
|
0002-9149
| |
|
DOI
|
|
|
|
10.1016/J.AMJCARD.2020.06.046
| |
|
Volume/pages
|
|
|
|
131
(2020)
, p. 27-32
| |
|
ISI
|
|
|
|
000566425500006
| |
|
Pubmed ID
|
|
|
|
32753268
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|